Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
Status:
Completed
Trial end date:
2018-08-09
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of filgotinib
and its metabolite, GS-829845, in participants with varying degrees of impaired hepatic
function relative to matched, healthy controls.